EMR
Emerson Electric Co.
EMR's fundamentals are strong, but it looks expensive: trading at 35x earnings, above its usual 23x. Analysts expect earnings growth.
EOSE
Eos Energy Enterprises, Inc.
There isn't enough reported data to score EOSE yet.
EMR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
EMR's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
EOSE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
EOSE's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
EMR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $49.84 | -70% |
| Fair | 22x | $107 | -36% |
| Forward | 23x | $167 | — |
| Expensive | 33x | $160 | -4.2% |
| Current | 35x | $167 | — |
Historical ranges are pointers, not guarantees.
EMR's PE is in its expensive range at 35x. If earnings grow as analysts expect, today's price would be 23x next year's earnings, in its fair range.
EOSE PE Valuation
EOSE has no meaningful PE right now: it lost money over the past year.
EMR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for EMR, with profitability improving.
EOSE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect EOSE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
EMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.30 | +53% |
| Q3 2026 | $4.78 | +18% |
| Q2 2026 | $4.57 | -1.7% |
| Q1 2026 | $4.33 | +3.6% |
| Q4 2025 | $4.09 | -2.4% |
| Q3 2025 | $4.04 | +18% |
| Q2 2025 | $4.65 | +56% |
| Q1 2025 | $4.18 | -78% |
| Q4 2024 | $4.19 | -78% |
EMR has the stronger earnings trend. Trailing diluted EPS is up 18% for EMR versus EOSE down 224%.
EOSE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$2.69 | +$0.85 |
| Q2 2023 | -$3.76 | -$1.00 |
| Q1 2023 | -$3.65 | -$0.86 |
| Q4 2022 | -$3.68 | -$1.32 |
| Q3 2022 | -$3.54 | +$5.19 |
EOSE is still losing money, but less than at its worst: $4.55 per share over the past year, against $8.73 at its worst in late 2021.
EMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.2B | +7.1% |
| Q2 2026 | $4.9B | +7% |
| Q1 2026 | $4.6B | +2.9% |
| Q4 2025 | $4.3B | +4.1% |
| Q3 2025 | $4.9B | +5.1% |
| Q2 2025 | $4.6B | +3.9% |
| Q1 2025 | $4.4B | +1.3% |
| Q4 2024 | $4.2B | +1.4% |
EMR's revenue has grown year over year for 12 quarters in a row: $5.2B last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +2.9 points |
| Q2 2026 | 19% | +2.7 points |
| Q1 2026 | 17% | +3.2 points |
| Q4 2025 | 18% | -0.7 points |
| Q3 2025 | 16% | +1.7 points |
| Q2 2025 | 16% | +5.7 points |
| Q1 2025 | 14% | -0.7 points |
| Q4 2024 | 19% | +15 points |
EMR has the edge over EOSE on profitability, with a higher operating margin.
EOSE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $82.7M | +171% |
| Q2 2026 | $68.8M | +351% |
| Q1 2026 | $57M | +445% |
| Q4 2025 | $58M | +700% |
| Q3 2025 | $30.5M | +3473% |
| Q2 2025 | $15.2M | +1597% |
| Q1 2025 | $10.5M | +58% |
| Q4 2024 | $7.3M | +9.7% |
EOSE has the edge over EMR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -96% | +105 points |
| Q2 2026 | -122% | +297 points |
| Q1 2026 | -139% | +367 points |
| Q4 2025 | -140% | +573 points |
| Q3 2025 | -201% | +6044 points |
| Q2 2025 | -419% | +2815 points |
| Q1 2025 | -506% | +117 points |
| Q4 2024 | -713% | -74 points |
EOSE's operating margin was −96% last quarter, up 105 points from the same quarter a year ago, near the top of its range since 2019.
EMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $917M | +8.9% |
| Q2 2026 | $1.3B | +35% |
| Q1 2026 | $694M | +351% |
| Q4 2025 | $602M | -13% |
| Q3 2025 | $842M | -8.1% |
| Q2 2025 | $977M | -2.1% |
| Q1 2025 | $154M | -77% |
| Q4 2024 | $694M | +105% |
EMR has the edge over EOSE on cash generation, producing positive trailing cash flow while its opponent burns cash.
EOSE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$105.1M | -$22.4M |
| Q2 2026 | -$107.4M | -$34.3M |
| Q1 2026 | -$154.8M | -$121M |
| Q4 2025 | -$75.2M | -$19.5M |
| Q3 2025 | -$82.7M | -$28.5M |
| Q2 2025 | -$73.2M | -$40.6M |
| Q1 2025 | -$33.8M | +$10.7M |
| Q4 2024 | -$55.8M | -$10.2M |
EOSE has burned cash in almost every quarter: −$443M over the past year, against −$246M the year before.
EMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +900K shares |
| 1 year | -0.8% | -4.7M shares |
| 3 years | -2.7% | -15.3M shares |
| 5 years | -6.6% | -39.8M shares |
| Available history | -8.5% | -52.1M shares |
EMR has the edge over EOSE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $102M |
| Q2 2026 | $356M |
| Q1 2026 | $292M |
| Q4 2025 | $250M |
| Q3 2025 | $20M |
| Q2 2025 | $25M |
| Q1 2025 | $223M |
| Q4 2024 | $899M |
EMR spent $1B buying back its own shares over the past year, down 14% from the year before.
EOSE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +63% | +213M shares |
| 1 year | +161% | +341M shares |
| 3 years | +888% | +497M shares |
EOSE has 553M diluted shares, up 161% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
EMR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.6x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 1.1x | Healthy |
EMR's net debt is about 2.1 years of its operating earnings (EBITDA), down from 2.6 years a year ago.
EOSE Net Leverage
EOSE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.0 | Neutral |
| Stochastic | 74.4 | Neutral |
EMR's weekly RSI is 64 (neutral) and its Stochastic is 74 (neutral).
EOSE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 7.4 | Oversold |
EOSE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
EMR PE vs Industrials Sector
| Metric | EMR | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 24x | 45% above |
| PE % | 89 | 58 | 31 pts above |
EMR is trading at 35x earnings, a 45% premium to the Industrials sector's median of 24x.
EOSE PE vs Industrials Sector
EOSE has no meaningful PE right now: it lost money over the past year.
EMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $162.4 | 2.8% above |
| 20 week MA | $155.2 | 7.6% above |
| 50 week MA | $146.6 | 14% above |
| 100 week MA | $135.9 | 23% above |
| 200 week MA | $117.9 | 42% above |
EMR has the edge over EOSE on trend strength, trading above more of its moving averages.
EOSE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 19% below |
| 20 week MA | $3.28 | 45% below |
| 50 week MA | $7.01 | 74% below |
| 100 week MA | $7.10 | 75% below |
| 200 week MA | $4.53 | 60% below |
EOSE is in a downtrend: it's below all five of its weekly moving averages, and 60% below its 200-week average.
EMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.5 | $80.0 | +4.5% |
| 2021 | $80.0 | $91.3 | +14% |
| 2022 | $91.3 | $95.5 | +4.7% |
| 2023 | $95.5 | $97.3 | +1.9% |
| 2024 | $97.3 | $125.7 | +29% |
| 2025 | $125.7 | $135.7 | +8% |
| 2026 YTD | $135.7 | $166.9 | +23% |
EMR has the edge over EOSE on returns for 2026, with the stronger performance.
EOSE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.72 | $19.2 | +98% |
| 2021 | $19.2 | $8.57 | -55% |
| 2022 | $8.57 | $1.08 | -87% |
| 2023 | $1.08 | $1.09 | +0.9% |
| 2024 | $1.09 | $5.17 | +374% |
| 2025 | $5.17 | $11.9 | +129% |
| 2026 YTD | $11.9 | $1.81 | -85% |
EOSE's yearly returns have swung widely, from +374% in 2024 to −87% in 2022. It's down 85% so far in 2026.